This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n9https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n17http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n16http://adisinsight.springer.com/drugs/
n11http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Pavinetant
rdf:type
wikidata:Q8386 owl:Thing dbo:ChemicalSubstance dbo:Drug n17:ChemicalObject
rdfs:label
Pavinetant
rdfs:comment
Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.
foaf:depiction
n11:MLE-4901.svg
dcterms:subject
dbc:Abandoned_drugs dbc:Quinolines dbc:Carboxamides dbc:NK3_receptor_antagonists dbc:Sulfonamides
dbo:wikiPageID
53980347
dbo:wikiPageRevisionID
1045199915
dbo:wikiPageWikiLink
dbr:Receptor_antagonist dbc:Quinolines dbr:Oral_administration dbr:Polycystic_ovary_syndrome dbr:Hot_flash dbr:Binding_selectivity dbc:Carboxamides dbr:Schizophrenia dbc:NK3_receptor_antagonists dbc:Sulfonamides dbr:AstraZeneca dbr:Small-molecule dbc:Abandoned_drugs dbr:Tachykinin_receptor_3
dbo:wikiPageExternalLink
n16:800038259
owl:sameAs
n9:2Y36R wikidata:Q27074725
dbp:wikiPageUsesTemplate
dbt:Neurokinin_receptor_modulators dbt:Genito-urinary-drug-stub dbt:Reflist dbt:Nervous-system-drug-stub dbt:Drugbox dbt:Abbrlink
dbo:thumbnail
n11:MLE-4901.svg?width=300
dbp:c
26
dbp:casNumber
941690
dbp:chebi
140478
dbp:chembl
3545233
dbp:chemspiderid
28189763
dbp:h
25
dbp:iupacName
3
dbp:kegg
D11345
dbp:n
3
dbp:o
3
dbp:pubchem
23649245
dbp:routesOfAdministration
dbr:Oral_administration
dbp:s
1
dbp:smiles
CC[C@@H]NCC2=CNSC
dbp:stdinchi
1
dbp:stdinchikey
QYTBBBAHNIWFOD-NRFANRHFSA-N
dbp:synonyms
MLE-4901; AZD-4901; AZD-2624; AZ-12472520
dbp:unii
3
dbp:width
225
dbo:abstract
Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.
prov:wasDerivedFrom
wikipedia-en:Pavinetant?oldid=1045199915&ns=0
dbo:wikiPageLength
4182
dbo:casNumber
941690-55-7
dbo:chEBI
140478
dbo:chEMBL
3545233
dbo:fdaUniiCode
3U471ZVC5K
dbo:kegg
D11345
dbo:pubchem
23649245
foaf:isPrimaryTopicOf
wikipedia-en:Pavinetant